TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

SNIPR Biome Secures Funding from CARB-X to Advance CRISPR Medicine SNIPR001 into Clinical Trials for Haematological Cancer Patients

Monday, April 22, 2024

SNIPR Biome ApS, a pioneer in precision medicine using CRISPR technology for microbial gene therapy, has secured $5.48 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This funding will co-fund a Phase 1b/2a clinical trial in hematological cancer patients.

The trial will assess SNIPR001, the first CRISPR-armed phage therapeutic targeting E. coli in the gut, to prevent E. coli bloodstream infections in hematological cancer patients undergoing hematopoietic stem-cell transplantation (HSCT). These patients are colonized with Fluoroquinolone Resistant (FQR) E. coli. Currently, there are no approved therapies for preventing bloodstream infections in these patients, despite advances in cancer therapy over the past decade.

Preclinical data published in Nature Biotechnology demonstrated SNIPR001’s ability to selectively target and remove antibiotic-resistant E. coli strains in the gut, potentially offering a safe treatment that preserves the rest of the gut microbiome. Phase 1 data published in 2023 showed that SNIPR001 was well tolerated in healthy individuals and reduced gut E. coli levels.

The Phase 1b/2a trial, anticipated to start later this year, will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered SNIPR001 in 24 patients across Europe and the United States.

CARB-X, dedicated to supporting early-stage antibacterial research, has collaborated with SNIPR in this field. The funding enables SNIPR to advance SNIPR001 into Phase 1b/2a clinical trials and pave the way for further fundraising to continue developing its pipeline of CRISPR-based therapies.

Dr. Christian Grøndahl, Co-founder and CEO of SNIPR Biome, emphasized the urgent need for effective therapies against antibiotic resistance, highlighting their approach using gene editing and synthetic biology to create precise treatments.

Erin Duffy PhD, Chief of Research & Development at CARB-X, expressed support for SNIPR001's development, aiming to establish a link between gut decolonization and infection prevention as a novel approach to antimicrobial resistance.

Funding for this research is supported by various organizations including the Biomedical Advanced Research and Development Authority, Wellcome, and Germany’s Federal Ministry of Education and Research.

SNIPR001, designed to prevent infections from spreading into the bloodstream, targets E. coli specifically in the gut. It has shown promising activity against multi-drug resistant strains of E. coli without affecting non-E. coli strains. With Fast-Track designation from the FDA, SNIPR001 holds potential as a preventative therapy for bloodstream infections in hematological cancer patients.


patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit